Intermediate-Term Risk of Prostate Cancer is Directly Related to Baseline Prostate Specific Antigen: Implications for Reducing the Burden of Prostate Specific Antigen Screening

Jonathan Gelfond(The University of Texas at San Antonio Health Science Center), Ian M. Thompson(The University of Texas at San Antonio Health Science Center), Javier Hernández(Vall d'Hebron Hospital Universitari), Donna P. Ankerst(The University of Texas at San Antonio Health Science Center), Robin J. Leach(The University of Texas at San Antonio Health Science Center), Kara Choate(The University of Texas at San Antonio Health Science Center)
The Journal of Urology
February 14, 2015
10.1016/j.juro.2015.02.043
Cited by 33

Related Papers

Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer
|Cell|1993|2.3k
Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update
|The Journal of Urology|2007|1.1k
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci
|Nature Genetics|2018|1k
Variation in the Definition of Biochemical Recurrence in Patients Treated for Localized Prostate Cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel Report and Recommendations for a Standard in the Reporting of Surgical Outcomes
|The Journal of Urology|2007|845
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
|The Lancet|2018|779